Leukemia & Lymphoma最新文献_第6页

Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-12 DOI: 10.1080/10428194.2025.2476655

Philip C Amrein, Frederic I Preffer, Geoffrey Fell, Eyal C Attar, Rupa Narayan, Traci M Blonquist, Andrew M Brunner, Gabriela S Hobbs, Hanno R Hock, Steven L McAfee, Jenna A Moran, Meghan K Bergeron, Julia E Foster, Christina Bertoli, Kristin McGregor, Christine Connolly, Tanya T Behnan, Tina T Som, Aura Y Ramos, Megan K Vartanian, Jennifer Lombardi Story, Donna S Neuberg, Amir T Fathi

{"title":"Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults.","authors":"Philip C Amrein, Frederic I Preffer, Geoffrey Fell, Eyal C Attar, Rupa Narayan, Traci M Blonquist, Andrew M Brunner, Gabriela S Hobbs, Hanno R Hock, Steven L McAfee, Jenna A Moran, Meghan K Bergeron, Julia E Foster, Christina Bertoli, Kristin McGregor, Christine Connolly, Tanya T Behnan, Tina T Som, Aura Y Ramos, Megan K Vartanian, Jennifer Lombardi Story, Donna S Neuberg, Amir T Fathi","doi":"10.1080/10428194.2025.2476655","DOIUrl":"https://doi.org/10.1080/10428194.2025.2476655","url":null,"abstract":"Outcome for acute myeloid leukemia (AML) patients aged >60 years is poor. Targeting the proteasome in AML is attractive, since leukemia stem cells demonstrate sensitivity to proteasome inhibition in preclinical models. Adults >60 years of age with newly diagnosed AML were enrolled. Induction consisted of cytarabine and daunorubicin with ixazomib provided on days 2, 5, 9, and 12. In a second phase, induction was followed by consolidation with cytarabine and ixazomib on days 2, 5, 9, and 12. Among the 39 patients enrolled, there was 1 DLT, grade 4 thrombocytopenia. There were no grade 3 or 4 neurotoxicity events attributable to ixazomib. The composite remission rate (CCR) was 69%. The median OS for the 39 patients was 38.5 months. The highest dose level (3 mg) of ixazomib planned for induction and consolidation in this trial has been reached safely and is the RP2D for both.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143605663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Time spent in healthcare among older patients with primary central nervous system lymphoma treated with high-dose methotrexate.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-11 DOI: 10.1080/10428194.2025.2477725

Colin Stewart, Carolyn Owen, Lesley Street, Kevin Hay, Sarah Perry, Peter Duggan, Mona Shafey, Alex Balogh, Jeffrey Cao, Neil Chua, Douglas Stewart, Robert Puckrin

引用次数: 0

Efficacy of first-line tagraxofusp in blastic plasmacytoid dendritic cell neoplasm with prior or concomitant hematologic malignancy: subgroup analysis of a pivotal trial.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-11 DOI: 10.1080/10428194.2025.2475338

Naveen Pemmaraju, Marina Konopleva, Kendra L Sweet, Anthony S Stein, David A Rizzieri, Eunice S Wang, Sumithira Vasu, Todd L Rosenblat, Alessandra Tosolini, Ira Gupta, Andrew A Lane

引用次数: 0

Patient and care partner perspectives on treatment decision-making in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): a Global nLPHL One Working Group (GLOW) study.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-10 DOI: 10.1080/10428194.2025.2474080

Ajay Major, Monica Palese, Anna Jones, Miranda Goes, Michael S Binkley, Jamie E Flerlage, Valerie McLaughlin Crabtree

引用次数: 0

Once weekly bortezomib decreases rates of peripheral neuropathy without diminishing efficacy as compared to twice weekly bortezomib in combination with lenalidomide, dexamethasone and daratumumab, a single center retrospective analysis.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-10 DOI: 10.1080/10428194.2025.2476656

Eleni Gaspar, Irvin Yi, Noffar Bar

引用次数: 0

A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-08 DOI: 10.1080/10428194.2025.2471499

Alessandra Tucci, Alessandro Re, Chiara Pagani, Luigi Marcheselli, Raffaella Marcheselli, Francesco Malaspina, Federica Cavallo, Vittorio Ruggero Zilioli, Manuela Zanni, Donato Mannina, Mariagrazia Michieli, Annalisa Arcari, Luca Castagna, Gerardo Musuraca, Michele Clerico, Francesco Merli, Monica Tani, Francesca Re, Guido Gini, Francesco Rotondo, Mauro Turrini, Giuseppe Rossi, Maria Christina Cox

{"title":"A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study.","authors":"Alessandra Tucci, Alessandro Re, Chiara Pagani, Luigi Marcheselli, Raffaella Marcheselli, Francesco Malaspina, Federica Cavallo, Vittorio Ruggero Zilioli, Manuela Zanni, Donato Mannina, Mariagrazia Michieli, Annalisa Arcari, Luca Castagna, Gerardo Musuraca, Michele Clerico, Francesco Merli, Monica Tani, Francesca Re, Guido Gini, Francesco Rotondo, Mauro Turrini, Giuseppe Rossi, Maria Christina Cox","doi":"10.1080/10428194.2025.2471499","DOIUrl":"https://doi.org/10.1080/10428194.2025.2471499","url":null,"abstract":"The FIL_RECANZ (ClinicalTrials.gov: NCT02371161) is a prospective study evaluating salvage with autologous stem cell transplantation (ASCT) in aggressive B-cell lymphoma patients aged 65 - 75, fit according to the FIL Geriatric Assessment (CGA). Seventy patients were analyzed who received salvage with three cycles of a platinum-based regimen. Response to salvage was 44% (21 complete, 10 partial remissions). Twenty-seven responding subjects underwent ASCT following BEAM/FEAM conditioning with a median of 5.6 × 106 CD34+ cells/kg reinfused: 24 (89%) obtained complete remission, in 22 lasting > 12 months. After a median of 28 months from ASCT, 2-year event-free survival was 54%, with the most common grade 3-4 non-hematological toxicity consisting of gastrointestinal (10%) and infectious (8%). No treatment-related mortality was recorded within 100 days following ASCT. Our data indicate that CGA enables fit older patients to undergo ASCT with favorable tolerance and efficacy. These results may serve as a benchmark to assess more effective pre-ASCT therapies.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real world efficacy of luspatercept in patients with lower-risk myelodysplastic syndromes/neoplasms (MDS); a single center study in a heavily pretreated cohort.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-07 DOI: 10.1080/10428194.2025.2470783

Marisa L Kometas, Fieke W Hoff, Jonathan Hyak, Vivian Irizarry-Gatell, Alejandro Marinos Velarde, Clayton Jackson, Julia Anderson, Fatma Neslihan Kalkan, Praveen Ramakrishnan Geethakumari, Julio Alvarenga Thiebaud, Weina Chen, Olga K Weinberg, Miguel D Cantu, Robert H Collins, Stephen S Chung, Yazan F Madanat

{"title":"Real world efficacy of luspatercept in patients with lower-risk myelodysplastic syndromes/neoplasms (MDS); a single center study in a heavily pretreated cohort.","authors":"Marisa L Kometas, Fieke W Hoff, Jonathan Hyak, Vivian Irizarry-Gatell, Alejandro Marinos Velarde, Clayton Jackson, Julia Anderson, Fatma Neslihan Kalkan, Praveen Ramakrishnan Geethakumari, Julio Alvarenga Thiebaud, Weina Chen, Olga K Weinberg, Miguel D Cantu, Robert H Collins, Stephen S Chung, Yazan F Madanat","doi":"10.1080/10428194.2025.2470783","DOIUrl":"https://doi.org/10.1080/10428194.2025.2470783","url":null,"abstract":"Anemia leads to transfusion dependence and decreases quality of life in LR-MDS patients. Our study retrospectively evaluates the efficacy and safety of luspatercept in the real-world treatment of anemia in LR-MDS, and the impact of patient and disease characteristics on hematologic improvement erythroid (HI-E). Baseline patient and disease characteristics, and transfusion burden (TB) were captured. HI-E was assessed in patients with ≥16 weeks of therapy per IWG 2018 criteria. Luspatercept achieved high rates (58.1%) of transfusion independence (TI) in heavily pretreated LR-MDS patients (median 58.3 weeks). Response was associated with serum EPO <100 mU/ml, but not with any other baseline characteristic. Adverse effects, including shortness of breath, falls, fatigue, and hypertension, precipitated discontinuation in 8%. Eleven percent progressed to HR-MDS or AML. Median overall survival was not reached and did not differ between responders and nonresponders (p=NS).","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143575762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Deintensification of radiation dose to 20 Gy for conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-06 DOI: 10.1080/10428194.2025.2470777

Jaeha Lee, Si Yeol Song, Young Seob Shin, Sung-Woo Kim, Ye Jin Yoo, Ji Hyeon Joo, Ho-Seok Sa, Dok Hyun Yoon, Sang-Wook Lee

引用次数: 0

Off-label use of recombinant activated factor VII in hemophagocytic lymphohistiocytosis patients with major bleeding.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-03-03 DOI: 10.1080/10428194.2025.2472923

Yahong You, Dina Suolitiken, Lin Wu, Yubo Pi, Leilei Chen, Deli Song, Zhengyang Song, Zhao Wang, Jingshi Wang

引用次数: 0

Determination of the appropriate chemotherapy for patients aged 80 years or older with diffuse large B cell lymphoma.